Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
NCT03883412 on ClinicalTrials.gov · last registry update 2026-08-12
Recruiting now, toward 60 participants. Due to report June 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Microvascular Blood Volume - change from baseline. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 28 February 2019 — 7 years so far. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- University of Virginia
- Sponsor type
- Other
- Enrollment
- 60
- Started
- 2019-02-28
- Primary completion
- 2027-06 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Microvascular Blood Volume - change from baseline
Conditions studied
Type2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.